Drug Name Zestoretic

In the distal tubules (dT), NaCl and water are again jointly reabsorbed. At the end of the nephron, this process involves an aldosterone- controlled exchange of Na+ against K+ or H+. In the collecting tubule (C), vasopressin (antidiuretic hormone, ADH) increases the epithelial permeability for water, which is drawn into the hyperosmolar milieu of the renal medulla and thus retained in the body.
Accordingly, disintegration and dissolution will take place in the duodenum at normal speed (A, track 1) and drug liberation per se is not retarded. The liberation of drug, hence the site and time-course of absorption, are subject to modification by appropriate production methods for matrix-type tablets, coated tablets, and capsules.

 

The therapeutic effect may result in part from a reaction with aldehydes, whereby polymerization of collagen molecules into fibrils is inhibited. Unwanted effects are: cutaneous damage (diminished resistance to mechanical stress with a tendency to form blisters), nephrotoxicity, bone marrow depression, and taste disturbances.
Frequent adverse reactions are: damage to skin and mucous membranes, renal toxicity, and blood dyscrasias. In addition, use is made of cytostatics and immune suppressants such as methotrexate (low dose, once weekly) and leflumomid as well as of cytokin antibodies (infliximab) and soluble cytokin receptors (etanercept).